{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:52:02Z","timestamp":1773658322949,"version":"3.50.1"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Emivirine (EMV), formerly known as MKC-442, is 6-benzyl-1-(ethoxymethyl)-5-isopropyl-uracil, a novel nonnucleoside reverse transcriptase inhibitor that displays potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity in vivo. EMV showed little or no toxicity towards human mitochondria or human bone marrow progenitor cells. Pharmacokinetics were linear for both rats and monkeys, and oral absorption was 68% in rats. Whole-body autoradiography showed widespread distribution in tissue 30 min after rats were given an oral dose of [<jats:sup>14<\/jats:sup>C]EMV at 10 mg\/kg of body weight. In rats given an oral dose of 250 mg\/kg, there were equal levels of EMV in the plasma and the brain. In vitro experiments using liver microsomes demonstrated that the metabolism of EMV by human microsomes is approximately a third of that encountered with rat and monkey microsomes. In 1-month, 3-month, and chronic toxicology experiments (6 months with rats and 1 year with cynomolgus monkeys), toxicity was limited to readily reversible effects on the kidney consisting of vacuolation of kidney tubular epithelial cells and mild increases in blood urea nitrogen. Liver weights increased at the higher doses in rats and monkeys and were attributed to the induction of drug-metabolizing enzymes. EMV tested negative for genotoxic activity, and except for decreased feed consumption at the high dose (160 mg\/kg\/day), with resultant decreases in maternal and fetal body weights, EMV produced no adverse effects in a complete range of reproductive toxicology experiments performed on rats and rabbits. These results support the clinical development of EMV as a treatment for HIV-1 infection in adult and pediatric patient populations.<\/jats:p>","DOI":"10.1128\/aac.44.1.123-130.2000","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T05:03:57Z","timestamp":1240376637000},"page":"123-130","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":44,"title":["Safety Assessment, In Vitro and In Vivo, and Pharmacokinetics of Emivirine, a Potent and Selective Nonnucleoside Reverse Transcriptase Inhibitor of Human Immunodeficiency Virus Type 1"],"prefix":"10.1128","volume":"44","author":[{"given":"G. M.","family":"Szczech","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Triangle Pharmaceuticals, Inc., Durham, North Carolina1;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Furman","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Triangle Pharmaceuticals, Inc., Durham, North Carolina1;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. R.","family":"Painter","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Triangle Pharmaceuticals, Inc., Durham, North Carolina1;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. W.","family":"Barry","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Triangle Pharmaceuticals, Inc., Durham, North Carolina1;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Borroto-Esoda","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Triangle Pharmaceuticals, Inc., Durham, North Carolina1;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. B.","family":"Grizzle","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Triangle Pharmaceuticals, Inc., Durham, North Carolina1;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Blum","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Triangle Pharmaceuticals, Inc., Durham, North Carolina1;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Sommadossi","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->University of Alabama, Birmingham, Alabama2; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Endoh","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Mitsubishi\u2013Tokyo Pharmaceuticals, Inc., Yokohama, Japan3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Niwa","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Mitsubishi\u2013Tokyo Pharmaceuticals, Inc., Yokohama, Japan3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Mitsubishi\u2013Tokyo Pharmaceuticals, Inc., Yokohama, Japan3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Moxham","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Triangle Pharmaceuticals, Inc., Durham, North Carolina1;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1073\/pnas.70.3.782","article-title":"An improved bacterial test system for the detection and classification of mutagens and carcinogens.","volume":"70","author":"Ames B. N.","year":"1973","unstructured":"Ames B. N. Lee F. D. Durston W. E. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc. Natl. Acad. Sci. USA 70 1973 782 786","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.12.2358"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.688"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/0006-2952(93)90232-L","article-title":"Effect of human serum on the in vitro anti HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-thymidine (HEPT) derivatives as related to their lipophilicity and serum protein binding.","volume":"45","author":"Baba M.","year":"1993","unstructured":"Baba M. Yuasa S. Niwa T. Yamamoto M. Yabuuchi S. Takashima H. Ubasawa M. Tanaka H. Miyasaka T. Walker R. T. Balzarini J. De Clercq E. Shigeta S. Effect of human serum on the in vitro anti HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-thymidine (HEPT) derivatives as related to their lipophilicity and serum protein binding. Biochem. Pharmacol. 45 1993 2507 2512","journal-title":"Biochem. Pharmacol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0026-895X(25)09081-9","article-title":"Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (\u2212)2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine.","volume":"49","author":"Balzarini J.","year":"1996","unstructured":"Balzarini J. Pelemans H. Perez-Perez M.-J. San-Felix A. Camarasa M.-J. De Clercq E. Karlsson A. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (\u2212)2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine. Mol. Pharmacol. 49 1996 882 890","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.2.358"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0166-3542(94)00074-I","article-title":"The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor, MKC-442, alone and in combination with other anti-HIV compounds.","volume":"26","author":"Brennan T. M.","year":"1995","unstructured":"Brennan T. M. Taylor D. L. Bridges C. G. Leyda J. P. Tyms A. S. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor, MKC-442, alone and in combination with other anti-HIV compounds. Antivir. Res. 26 1995 173 187","journal-title":"Antivir. Res."},{"key":"e_1_3_2_9_2","unstructured":"Bruning J. L. Kintz B. L. Pearson product-moment correlation Computational handbook of statistics 3rd ed. 1987 176 180 Harper Collins Publishers Glenview Ill"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0090-9556(25)07348-9","article-title":"Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.","volume":"24","author":"Chiba M.","year":"1996","unstructured":"Chiba M. Hensleigh M. Nishime J. Balani S. Lin J. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24 1996 307 313","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(96)00562-X"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/med.2610130303","article-title":"HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.","volume":"13","author":"De Clerq E.","year":"1993","unstructured":"De Clerq E. HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 13 1993 229 258","journal-title":"Med. Res. Rev."},{"key":"e_1_3_2_13_2","first-page":"153","article-title":"The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.","volume":"38","author":"De Clerq E.","year":"1998","unstructured":"De Clerq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antivir. Res. 38 1998 153 179","journal-title":"Antivir. Res."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/(SICI)1099-1654(199606)6:2<97::AID-RMV168>3.0.CO;2-4","article-title":"What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections?","volume":"6","author":"De Clerq E.","year":"1996","unstructured":"De Clerq E. What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Med. Virol. 6 1996 97 117","journal-title":"Med. Virol."},{"key":"e_1_3_2_15_2","first-page":"735","article-title":"Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS?","volume":"50","author":"De Clerq E.","year":"1995","unstructured":"De Clerq E. Balzarini J. Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS? Il Pharmaco 50 1995 735 747","journal-title":"Il Pharmaco"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/362359a0"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1358\/dof.1998.023.07.466749","article-title":"MKC-442: a potent and selective non-nucleoside reverse transcriptase inhibitor.","volume":"23","author":"Furman P. A.","year":"1998","unstructured":"Furman P. A. Moxham C. MKC-442: a potent and selective non-nucleoside reverse transcriptase inhibitor. Drugs Future 23 1998 718 724","journal-title":"Drugs Future"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1358\/dof.1998.023.02.445974","article-title":"Efavirenz.","volume":"23","author":"Graul A.","year":"1998","unstructured":"Graul A. Rabasseda X. Casta\u00f1er J. Efavirenz. Drugs Future 23 1998 133 141","journal-title":"Drugs Future"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90522-7"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0165-7992(90)90153-B","article-title":"The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange-coated slides.","volume":"245","author":"Hayashi M.","year":"1990","unstructured":"Hayashi M. Morita T. Kodama Y. Sofuni T. Ishidate M. The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange-coated slides. Mutat. Res. 245 1990 245 249","journal-title":"Mutat. Res."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/oxfordjournals.jbchem.a135653","article-title":"Isolation of a cytochrome P-450 that catalyzes the 25-hydroxylation of vitamin D3 from rat liver microsomes.","volume":"99","author":"Hayashi S.","year":"1986","unstructured":"Hayashi S. Noshiro M. Okuda K. Isolation of a cytochrome P-450 that catalyzes the 25-hydroxylation of vitamin D3 from rat liver microsomes. J. Biochem. 99 1986 1753 1763","journal-title":"J. Biochem."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm960056x"},{"key":"e_1_3_2_23_2","first-page":"313","article-title":"Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?","volume":"3","author":"Kilby J. M.","year":"1994","unstructured":"Kilby J. M. Saag M. S. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? Infect. Agents Dis. 3 1994 313 323","journal-title":"Infect. Agents Dis."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0165-1218(87)90019-X","article-title":"A guide for the performance of the Chinese hamster ovary cell hypoxanthine-guanine phosphoribosyl transferase gene mutation assay.","volume":"189","author":"Li A. P.","year":"1987","unstructured":"Li A. P. Carver J. H. Choy W. N. Hsie A. W. Gupta R. S. Loveday K. S. O'Neill J. P. Riddle J. C. Stankowski L. F. Yang L. L. A guide for the performance of the Chinese hamster ovary cell hypoxanthine-guanine phosphoribosyl transferase gene mutation assay. Mutat. Res. 189 1987 135","journal-title":"Mutat. Res."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/095632029100200601","article-title":"Review: didanosine.","volume":"2","author":"McLaren C.","year":"1991","unstructured":"McLaren C. Datema R. Knupp C. A. Buroker R. A. Review: didanosine. Antivir. Chem. Chemother. 2 1991 321 328","journal-title":"Antivir. Chem. Chemother."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1701568"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1517\/13543784.5.9.1183","article-title":"Nevirapine: a review of its development, pharmacological profile and potential for clinical use.","volume":"5","author":"Murphy R. L.","year":"1996","unstructured":"Murphy R. L. Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp. Opin. Investig. Drugs 5 1996 1183 1199","journal-title":"Exp. Opin. Investig. Drugs"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0166-3542(96)00946-1","article-title":"Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells.","volume":"31","author":"Okamoto M.","year":"1996","unstructured":"Okamoto M. Makino M. Yamada K. Nakade K. Yuasa S. Baba M. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells. Antivir. Res. 31 1996 69 77","journal-title":"Antivir. Res."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/362355a0"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF03259093","article-title":"Nevirapine.","volume":"6","author":"Patel S. S.","year":"1996","unstructured":"Patel S. S. Benfield P. Nevirapine. Clin. Immunother. 6 1996 307 317","journal-title":"Clin. Immunother."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1097\/00002030-199710001-00009","article-title":"Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir.","volume":"11","author":"Pialoux G.","year":"1997","unstructured":"Pialoux G. Fournier S. Moulignier A. Poveda J.-D. Clavel F. Dupont B. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. AIDS 11 1997 1302 1303","journal-title":"AIDS"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00002030-199704000-00010","article-title":"Three-drug combinations of MKC-442, lamivudine, and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.","volume":"11","author":"Piras G.","year":"1997","unstructured":"Piras G. Nakade K. Yuasa S. Baba M. Three-drug combinations of MKC-442, lamivudine, and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1. AIDS 11 1997 469 475","journal-title":"AIDS"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632029500600201"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.7.997"},{"key":"e_1_3_2_35_2","first-page":"715","article-title":"The new non-nucleoside reverse transcriptase inhibitors.","volume":"13","author":"Swindells S.","year":"1996","unstructured":"Swindells S. Gundelman H. E. The new non-nucleoside reverse transcriptase inhibitors. Infect. Med. 13 1996 715 719","journal-title":"Infect. Med."},{"key":"e_1_3_2_36_2","first-page":"117","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection.","volume":"273","author":"Wie X.","year":"1995","unstructured":"Wie X. Ghosh S. K. Taylor M. E. Johnson V. A. Emini E. A. Deutsch P. Lifson J. D. Bonhoeffer S. Nowak M. A. Hahn B. H. Saag M. S. Shaw G. M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 273 1995 117 122","journal-title":"Nature"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00008571-199312000-00003","article-title":"Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in a substrate concentration-dependent manner.","volume":"3","author":"Yasumori T.","year":"1993","unstructured":"Yasumori T. Nagata K. Yang S. Chen L. Murayama N. Yamazoe Y. Kato R. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in a substrate concentration-dependent manner. Pharmacogenetics 3 1993 291 301","journal-title":"Pharmacogenetics"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0026-895X(25)13288-4","article-title":"Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.","volume":"44","author":"Yuasa S.","year":"1993","unstructured":"Yuasa S. Sadakata Y. Takashima H. Kouichi S. Inouye N. Ubasawa M. Baba M. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol. Pharmacol. 44 1993 895 900","journal-title":"Mol. Pharmacol."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.1.123-130.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.1.123-130.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T03:41:15Z","timestamp":1739072475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.1.123-130.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1128\/AAC.44.1.123-130.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.1.123-130.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1]]},"assertion":[{"value":"1998-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-09-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}